Please select the eligibility criteria that correspond to the clinical trial below.
Title: Music to Improve Sleep Quality in Adults With Depression and Insomnia: a Randomized Controlled Trial Using Mixed Methods
Brief Summary: Insomnia is a common sleep disorder for patients with depression. This has a major impact on the quality of life for the individual.

The aim is to investigate, whether music intervention is effective in

1. improving sleep quality,
2. reducing symptoms of depression and
3. improving quality of life

Participants use a sound pillow and selected music in the The Music Star app at home as a sleep aid in 4 weeks.


Options:
A: Inclusion Criteria:

* Out patients in treatment for depression in psychiatry, Unit for Depression, Aalborg University Hospital.
* ICD-10 diagnosis of unipolar depression F32 or F33.
* Sleeping problems identified by HAM-D by a total score of 3 on sleep items 4-6, or a single score = 2 on at least one sleep item.
* Following treatment standards according to national guidelines.(pharmacological treatment, psychotherapy, psycho education, Electro Convulsive Therapy).
* 4 weeks of treatment and/or in stabilized pharmacological treatment

Exclusion Criteria:

* ICD-10 diagnosis of depression F32 or F33 and psychotic episodes
* substance or alcohol abuse
* sentence to treatment by law
* restless legs syndrome
* obstructive sleep apnoea or other organic sleep disorders
* hearing loss
* dislike of music
B: Inclusion Criteria:

* 18 and older
* diagnosed with breast cancer, lung cancer, or gastro-intestinal cancer

Exclusion Criteria:

* Under 18
* past cancer(s)
C: Inclusion Criteria:

1. Teenagers at the ages 12-17
2. Four or five (dependent on their overall plan of medical treatment) consecutive courses of chemotherapy administrated at the involved child cancer units and (administered) over a period of minimum 24 hours incl. hydration with assumed moderate to severe nausea and vomiting.

   The specific type of chemotherapy may vary across the four/five consecutive courses but shall include one of the following moderate and/or highly emetogenic types of chemotherapy:

   Moderate emetogenic chemotherapy:
   * Carboplatin
   * Cyclophosphamide \<1500 mg/m2
   * Cytarabine \>1 g/m2
   * Daunorubicin
   * Doxorubicin
   * Epirubicin
   * Idarubicin
   * Ifosfamide
   * Mitoxantrone
   * Methotrexate \>1000 mg/m2

   Highly emetogenic chemotherapy:
   * Cisplatin \>25 mg/m2
   * Cyclophosphamide \>1500 mg/m2
   * Dacarbazine
3. Understand Norwegian/Danish
4. Read Norwegian/Danish (teenagers or alternatively parents)
5. No significant hearing impairment
6. Informed written consent (teenagers ≥16 years and parents)
7. Subsequent verbal confirmation of written informed consent before enrolment in study

Exclusion Criteria:

1. Previous and/or acute psychiatric diagnosis
2. Cognitive and mental deficits or impaired functioning
D: Inclusion Criteria:

* Age 60 and older
* Physician diagnosis of probable ADRD using standard assessments and diagnostic criteria
* Presence of sleep problems determined first during phone screening using NPI sleep disorders item, then using proxy-rated Sleep Disorders Inventory (SDI) (presence of at least one sleep disturbance symptom of moderate severity)
* Stable dose of psychotropic medications, sedatives/hypnotics, anti-dementia or opioids in the past 90 days (typical time frame in clinical trials) prior to enrollment to minimize confounding effects of medications
* Tolerates and agrees to wear wrist actigraph
* Responsive to their environment (e.g., able to understand short commands)
* Sufficient English to complete questionnaires

Exclusion Criteria:

* Planned transition to another residential or institutional care setting in less than 3 months
* Hearing impairment (defined as inability to hear a normal speaking voice at a distance of 1-1/2 feet)
* Presence of extrapyramidal symptoms affecting non-dominant hand which may include persons with the following diagnoses: schizophrenia, bipolar disorder, Huntington's disease, Parkinson's disease, Lewy Body dementia due to REM sleep disorders
* Currently enrolled in an interventional clinical trial for ADRD aimed to improve sleep
* Acute sleep disruption within 2 weeks of screening as it may indicate sleep disorders not related to ADRD or delirium
* End stage disease (i.e. cancer, bed bound)

Answer: A